Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046228 | 0.86 | L3MBTL1 (0.60) | L3MBTL1POLBSMN1; SMN2GLANPSR1 | |
| SCHEMBL28599041 | 0.85 | NPSR1 (0.42) | L3MBTL1POLBSMN1; SMN2GLANPSR1 | |
| SCHEMBL10339023 | 0.83 | L3MBTL1 (0.61) | L3MBTL1POLBSMN1; SMN2GLANPSR1 | |
| SCHEMBL5000594 | 0.83 | NPSR1 (0.67) | L3MBTL1POLBSMN1; SMN2GLANPSR1 | |
| SCHEMBL9698448 | 0.82 | LTB4R (0.47) | NPSR1KDM4EALDH1A1GAA | |
| SCHEMBL29598836 | 0.81 | TDP1 (0.45) | L3MBTL1POLBSMN1; SMN2GLANPSR1 | |
| SCHEMBL7622740 | 0.78 | PTGS2 (0.46) | KDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL8496774 | 0.78 | ALDH1A1 (0.42) | L3MBTL1SMN1; SMN2NPSR1KDM4EALDH1A1 | |
| SCHEMBL2437604 | 0.78 | CYP3A4 (0.53) | SMN1; SMN2NPSR1KDM4EALDH1A1TDP1 | |
| SCHEMBL6699939 | 0.77 | L3MBTL1 (0.57) | L3MBTL1POLBSMN1; SMN2GLANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023168066-A9 | OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-4337639-A1 | NAMPT INHIBITORS AND USES THEREOF | Remedy Plan, Inc. (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2023201005-A2 | HYDROPHOBIC POLYMER AEROGELS | AEROGEL TECHNOLOGIES, LLC (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023168066-A1 | OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| WO-2023168045-A1 | HYDROXY/AMINO OXIME-BASED HOT MELT ADHESIVES FOR REWORK, REPAIR AND RECYCLE | CONAGEN INC. (US) | 2023-09-07 | — | — | WO | disclosed |
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2022241257-A1 | NAMPT INHBITORS AND USES THEREOF | REMEDY PLAN, INC. (US) | 2022-11-17 | — | — | WO | disclosed |
| EP-3923989-A1 | MULTIVALENT LIGAND CLUSTERS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Mitotherapeutix LLC (US) | 2021-12-22 | — | — | EP | disclosed |
| WO-2021216828-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-10-28 | — | — | WO | disclosed |
| EP-3883945-A1 | C11-CYCLIC SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2021-09-29 | — | — | EP | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192664-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| EP-3234175-A1 | ENZYMATIC ACTIVITY ASSAYS FOR I2S | Shire Human Genetic Therapies, Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017062622-A1 | SUPRAMOLECULAR MODIFICATION OF PROTEINS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017015555-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017015575-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-01-26 | — | — | WO | disclosed |
| WO-2016100603-A9 | ENZYMATIC ACTIVITY ASSAYS FOR I2S | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2016-08-11 | — | — | WO | disclosed |
| WO-2016100603-A1 | ENZYMATIC ACTIVITY ASSAYS FOR I2S | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158159-A1 | CHIMERIC DEGRADERS OF CYCLIN-DEPENDENT KINASE 9 AND USES THEREOF | CDK9, CDK19, CRBN | L3MBTL1 2637/4885POLB 1494/4885SMN1; SMN2 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.